Sort
15,273 grants matching “antimicrobial resistance”
Host Defense Against HIV-related Pulmonary Infections
$1,300,680Judd E Shellito · Lsu Health Sciences Center · P01 · FY2007 · HL
Innovative technologies to transform antibiotic discovery. Project 2 Engineering antibiotic sensitization therapies
$1,300,078Paul Clark Blainey · Broad Institute, Inc. · U19 · FY2019 · AI
Identification of novel MDR antimicrobials from insect-Streptomyces symbioses
$1,295,717David R Andes · University Of Wisconsin-Madison · U19 · FY2023 · AI
Structural Genomics Centers for Infectious Diseases
$1,295,009Karla Fullner Satchell · Northwestern University At Chicago · N01 · FY2019 · AI
Establishing a Gram-Negative Permeation Rule Set Leveraging a Unique Small Molecule Library
$1,294,532Steven Armen Boyd · Venatorx Pharmaceuticals, Inc. · R01 · FY2020 · AI
Innate inflammatory responses during pulmonary infections
$1,293,685Katrin Mayer-Barber · National Institute Of Allergy And Infectious Diseases · ZIA · FY2020 · AI
Task A43: Establishment of a Chronic Bacterial Lung Infection Model in Ã-ENaC Mice
$1,293,315Joanne Shanklin · Univ Of North Carolina Chapel Hill · N01 · FY2020 · AI
Epithelial Genes in Allergic Inflammation
$1,287,307Gurjit K Khurana Hershey · Cincinnati Childrens Hosp Med Ctr · U19 · FY2020 · AI
Vaccine and Treatment Evaluation Units
$1,282,926Nadine Georges Rouphael · Emory University · UM1 · FY2025 · AI
AI-3 Inhibitors as treatment for bacterial infections
$1,282,801Vanessa Sperandio · Ut Southwestern Medical Center · U01 · FY2011 · AI
VACCINE AND TREATMENT EVALUATION UNITS: PHASE IV TRIAL TO EVALUATE THERAPEUTICS FOR RESISTANT BACTERIAL INFECTIONS
$1,282,074Mark Joseph Mulligan · Emory University · N01 · FY2017 · AI
Phase 1 Clinical Trial Units for Therapeutics Against Infectious Diseases: Evaluation of Therapeutics for Resistant Bacterial Infections
$1,281,164Rob Caudle · Duke University · N01 · FY2017 · AI
A Clinical Trial of Antimicrobial Skin Substitutes for Treatment of Diabetic Ulce
$1,281,128Mary A. Lokuta · Stratatech Corporation · R44 · FY2011 · DK
CONTROL OF PERIODONTAL INFECTIONS
$1,277,464Forsyth Institute · P01 · FY2003 · DE
Studies of Receptor Interactions and Effects of Alarmins
$1,276,907Joost J Oppenheim · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA
Genes/Pathways for ATG Gene-dependent Inhibition of Viruses & Parasite Infection
$1,276,123Herbert W Virgin · Washington University · U19 · FY2017 · AI
Structural characterization of OM proteins from Gram-negative pathogens
$1,270,075Susan Buchanan · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2015 · DK
Technology development for point-of-care detection and antimicrobial susceptibility testing of Neisseria gonorrhoeae
$1,267,227Tza-Huei Jeff Wang · Johns Hopkins University · R01 · FY2019 · AI
Identification of novel MDR antimicrobials from human microbiome symbioses
$1,266,106Nasia Safdar · University Of Wisconsin-Madison · U19 · FY2023 · AI
FilmArray Direct: Rapid Diagnosis of Antimicrobial-Resistant Pathogens from Blood
$1,265,369Andrew Hemmert · Biofire Diagnostics, Llc · R01 · FY2016 · AI
Combatting AntiMicrobial Resistance in Africa Using Data Science (CAMRA)
$1,264,691Christian T. Happi · Redeemer'S University · U54 · FY2024 · TW
Molecular mechanisms of immune evasion in Staphylococcus aureus
$1,262,516Michael Otto · National Institute Of Allergy And Infectious Diseases · ZIA · FY2011 · AI
Technology development for point-of-care detection and antimicrobial susceptibility testing of Neisseria gonorrhoeae
$1,259,228Tza-Huei Jeff Wang · Johns Hopkins University · R01 · FY2020 · AI
Innovative technologies to transform antibiotic discovery. Project 4 Infection site-specific amplification of antimicrobial conjugates
$1,257,364Deborah T Hung · Broad Institute, Inc. · U19 · FY2023 · AI
HLS- Cyclic CAR peptide: a targeted therapy for pulmonary hypertension
$1,255,432Paul B Yu · Vascular Biosciences · R42 · FY2018 · HL